Top

03-09-2015 | Osteoporosis | Review | Article

Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis

Journal: Calcified Tissue International

Authors: Le T. Duong, Albert T. Leung, Bente Langdahl

Abstract

Cathepsin K (CatK), a cysteine protease, is highly expressed by osteoclasts and very efficiently degrades type I collagen, the major component of the organic bone matrix. Robust genetic and pharmacological preclinical studies consistently demonstrate that CatK inhibition increases bone mass, improves bone microarchitecture and strength. Recent advances in the understanding of the molecular and cellular mechanisms involved in bone modeling and remodeling suggest that inhibition of CatK decreases bone resorption, but increases the number of cells of osteoclast lineage. This in turn maintains the signals for bone formation, and perhaps may even increase bone formation on some cortical surfaces. Several CatK inhibitors, including relacatib, balicatib, odanacatib and ONO-5334 had entered clinical development for metabolic bone disorders with increased bone resorption, such as postmenopausal osteoporosis. However, odanacatib (ODN) is the only candidate continuing in development. ODN is a highly selective oral CatK inhibitor dosed once-weekly in humans. In a Phase 2 clinical trial, postmenopausal women treated with ODN had sustained reductions of bone resorption markers, while bone formation markers returned to normal after an initial decline within the first 2 years on treatment. In turn areal bone mineral density increased continuously at both spine and hip for up to 5 years. ODN has also been demonstrated to improve bone mass in women with postmenopausal osteoporosis previously treated with alendronate and in men with osteoporosis. ODN is currently in a worldwide Phase 3 fracture outcome trial for the treatment of postmenopausal osteoporosis with interim results supporting its anti-fracture efficacy at the spine, hip and non-vertebral sites.

Study to determine the effects of doses of relacatib on the metabolism of acetaminophen, ibuprofen and atorvastatin. 2006. https://www.clinicaltrials.gov/ct2/show/NCT00411190?term=relacatib&rank=1. Accessed 15 June 2015

Data from pivotal phase 3 fracture outcomes study for odanacatib, an investigational oral, once-weekly treatment for osteoporosis. 2014. http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st. Accessed 15 June 2015

Adami S, Supronik J, Haha T, Brown JP, Garnero P, Haemmerle S.Ortmann CE, Bousset F, TrechelU (2006) Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res, 21(suppl 1)

Amin S, Kopperdhal DL, Melton LJ III, Achenbach SJ, Therneau TM, Riggs BL, Keaveny TM, Khosla S (2011) Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res 26(1):1593–1600CrossRefPubMedPubMedCentral

Anderson MS, Gendrano IN, Liu C, Jeffers S, Mahon C, Mehta A, Mostoller K, Zajic S, Morris D, Lee J, Stoch SA (2014) Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. J Clin Endocrinol Metab 99(1):552–560CrossRefPubMed

Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(1):677–692CrossRefPubMed

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(1):1809–1822CrossRefPubMed

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(1):243–254CrossRefPubMedPubMedCentral

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(1):972–980CrossRefPubMed

10.

Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98(1):4483–4492CrossRefPubMedPubMedCentral

11.

Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A (2015) Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos Int 26(1):699–712CrossRefPubMedPubMedCentral

12.

Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, Dasilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947PubMed

13.

Bonnet N, Duong LT, Ferrari S (2014) Increased periostin in cortical bone of cathepsin K knock-out mice is responsible for higher cortical bone mass and strength. J Bone Miner Res, 29(suppl 1)

14.

Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, Dasilva C, Scott BB, Le Bailly DT, Leung AT, Gurner D (2013) Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. J Clin Endocrinol Metab 98(2):4727–4735CrossRefPubMed

15.

Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98(1):571–580CrossRefPubMed

16.

Bromme D, Lecaille F (2009) Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 18:585–600CrossRefPubMedPubMedCentral

17.

Cabal A, Jayakar RY, Sardesai S, Phillips EA, Szumiloski J, Posavec DJ, Mathers PD, Savitz AT, Scott BB, Winkelmann CT, Motzel S, Cook L, Hargreaves R, Evelhoch JL, Dardzinski BJ, Hangartner TN, McCracken PJ, Duong LT, Williams DS (2013) High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone 56(2):497–505CrossRefPubMed

18.

Chavassieux P, Asser KM, Segovia-Silvestre T, Neutzsky-Wulff AV, Chapurlat R, Boivin G, Delmas PD (2008) Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 23(1):1076–1083CrossRefPubMed

19.

Chen W, Yang S, Abe Y, Li M, Wang Y, Shao J, Li E, Li YP (2007) Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 16:410–423CrossRefPubMedPubMedCentral

20.

Chia LY, Walsh NC, Martin TJ, Sims NA (2015) Isolation and gene expression of haematopoietic-cell-free preparations of highly purified murine osteocytes. Bone 72(1):34–42CrossRefPubMed

21.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(1):756–765CrossRefPubMed

22.

Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, Duong LT (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27(2):524–537CrossRefPubMed

23.

Delaisse JM (2014) The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation. Bonekey Rep 3(1):561PubMedPubMedCentral

24.

Duong LT (2012) Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep 1(1):67PubMedPubMedCentral

25.

Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S (2014) Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res 29(1):458–466CrossRefPubMed

26.

Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, Dasilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:251CrossRef

27.

Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, de Papp A (2015) Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial. J Bone Miner Res 30(2):30–38CrossRefPubMed

28.

Engelke K, Nagase S, Fuerst T, Small M, Kuwayama T, Deacon S, Eastell R, Genant HK (2014) The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 29(1):629–638CrossRefPubMed

29.

Everts V, Hou WS, Rialland X, Tigchelaar W, Saftig P, Bromme D, Gelb BD, Beertsen W (2003) Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 73(1):380–386CrossRefPubMed

30.

Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Masse F, Riendeau D, Toulmond S, Percival MD (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 48:7535–7543CrossRefPubMed

31.

Ferrari S (2014) Future directions for new medical entities in osteoporosis. Best Pract Res Clin Endocrinol Metab 28(1):859–870CrossRefPubMed

32.

Fratzl-Zelman N, Roschger P, Fisher JE, Duong LT, Klaushofer K (2013) Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study. Calcif Tissue Int 92(1):261–269CrossRefPubMed

33.

Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42:200–211CrossRefPubMed

34.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne JP, Leger S, LeRiche T, Li CS, Masse F, McKay DJ, Li CS, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Percival MD, Robichaud J, Rodan GA, Rodan SB, Seto GA, Therien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923–928CrossRefPubMed

35.

Harvey N, Dennison E, Cooper C (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6(1):99–105CrossRefPubMed

36.

Henriksen K, Karsdal MA, Martin TJ (2014) Osteoclast-derived coupling factors in bone remodeling. Calcif Tissue Int 94(1):88–97CrossRefPubMed

37.

Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM (1999) Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14(4):536–545CrossRefPubMed

38.

Ho N, Punturieri A, Wilkin D, Szabo J, Johnson M, Whaley J, Davis J, Clark A, Weiss S, Francomano C (1999) Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein. J Bone Miner Res 14:1649–1653CrossRefPubMed

39.

Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei Med J 45(1):676–682CrossRefPubMed

40.

Jerome C, Missbach M, Gamse R (2011) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 22(2):3001–3011CrossRefPubMed

41.

Kassahun K, Black WC, Nicoll-Griffith D, McIntosh I, Chauret N, Day S, Rosenberg E, Koeplinger K (2011) Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. Drug Metab Dispos 39(1):1079–1087CrossRefPubMed

42.

Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40:122–131CrossRefPubMed

43.

Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez PJ, Denker A, Lombardi A, Le Bailly DT, Dasilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27(1):2251–2258CrossRefPubMed

44.

Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M (2002) A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30:746–753CrossRefPubMed

45.

Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT (2011) The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 49:623–635CrossRefPubMed

46.

Li CY, Jepsen KJ, Majeska RJ, Zhang J, Ni R, Gelb BD, Schaffler MB (2006) Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21(109):865–875CrossRefPubMed

47.

Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(1):2024–2030CrossRefPubMed

48.

Lotinun S, Kiviranta I, Neff L, Vacher J, Vuorio E, Horne W, Sabatakos G, Baron R (2010) Disruption of cathepsin K in the osteoclast lineage increased bone formation through coupling-dependent mechanism. J Bone Miner Res, 25(suppl 1)

49.

Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R (2013) Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Investig 123(1):666–681PubMedPubMedCentral

50.

Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(1):305–311PubMed

51.

Masarachia PJ, Pennypacker BL, Pickarski M, Scott KR, Wesolowski GA, Smith SY, Samadfam R, Goetzmann JE, Scott BB, Kimmel DB, Duong LT (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27(1):509–523CrossRefPubMed

52.

McClung MR, Chines A, Brown JP, Diez-Perez A, Resch H, Caminis J, Bolognese MA, Goemarere S, Bone HG, Zanchetta J, Maddox J, Rosen O, Bray S, Grauer A (2014) Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. J Bone Miner Res, 29(suppl 1)

53.

McClung MR, Langdahl B, Papapoulos S, Saag K, Bone H, Rybak-Feiglin A, Cohn D, DaSilva CA, Massaad R, Santora AC, Scott BB, Kaufman KD, Verbruggen N, Leung A, Lombardi A (2015) Odanacatib Anti-fracture efficacy and safety in post-menopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial (LOFT). IBMS BoneKEy, 13(677), OC4.4. 2015

54.

Morko JP, Soderstrom M, Saamanen AM, Salminen HJ, Vuorio EI (2004) Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 63:649–655CrossRefPubMedPubMedCentral

55.

Motyckova G, Fisher DE (2002) Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med 2(12):407–421CrossRefPubMed

56.

Nagase S, Hashimoto Y, Small M, Ohyama M, Kuwayama T, Deacon S (2012) Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women. Br J Clin Pharmacol 74(6):959–970CrossRefPubMedPubMedCentral

57.

Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S (2014) Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study. Osteoporos Int 25(1):367–376CrossRefPubMed

58.

Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23(2):1591–1600CrossRefPubMed

59.

Ochi Y, Yamada H, Mori H, Kawada N, Kayasuga R, Nakanishi Y, Tanaka M, Imagawa A, Ohmoto K, Kawabata K (2014) ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats. J Bone Miner Metab 32(1):645–652CrossRefPubMed

60.

Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49(1):1351–1356CrossRefPubMed

61.

Orwoll E, Adami S, Binkley N, Chapurlat R, Langdahl B, Doleckyi S, Giezek H, Scott BB, Santora AC (2014) Randomized controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. J Bone Miner Res, 29(suppl 1)

62.

Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellstrom D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27(1):694–701CrossRefPubMedPubMedCentral

63.

Pennypacker B, Shea M, Liu Q, Masarachia P, Saftig P, Rodan S, Rodan G, Kimmel D (2009) Bone density, strength, and formation in adult cathepsin K (−/−) mice. Bone 44:199–207CrossRefPubMed

64.

Pennypacker BL, Chen CM, Zheng H, Shih MS, Belfast M, Samadfam R, Duong LT (2014) Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J Bone Miner Res 29(1):1847–1858CrossRefPubMed

65.

Pennypacker BL, Duong LT, Cusick TE, Masarachia PJ, Gentile MA, Gauthier JY, Black WC, Scott BB, Samadfam R, Smith SY, Kimmel DB (2011) Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 26:252–262CrossRefPubMed

66.

Pennypacker BL, Oballa RM, Levesque S, Kimmel DB, Duong LT (2013) Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits. BMC Musculoskelet Disord 14(1):344CrossRefPubMedPubMedCentral

67.

Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, Wysolmerski J, Bonewald LF (2012) Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 27(1):1018–1029CrossRefPubMedPubMedCentral

68.

Recker R, Dempster DW, De Villiers T, Langdahl B, Miller PD, Valter I, Zerbini C, Cohn D, Doleckyi S, Duong LT, Scott BB, Verbruggen N, Santora AC (2014) Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial (LOFT). J Bone Miner Res, 29(suppl 1)

69.

Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol, 2

70.

Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A (2014) Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 94(1):153–157CrossRefPubMed

71.

Runger TM, Adami S, Benhamou CL, Czerwinski E, Farrerons J, Kendler DL, Mindeholm L, Realdi G, Roux C, Smith V (2012) Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 66(1):e89–e96CrossRefPubMed

72.

Russo CR, Lauretani F, Seeman E, Bartali B, Bandinelli S, Di Iorio A, Guralnik J, Ferrucci L (2006) Structural adaptations to bone loss in aging men and women. Bone 38(7):112–118CrossRefPubMed

73.

Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, Suter A, von Figura K (2000) Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv Exp Med Biol 477(1):293–303PubMed

74.

Scott K, Gentile MA, Horrel C, Winkelmann CT, Crawford R, Szumiloski J, Samadfam R, Smith SY, Duong LT (2012) Efficacy of switching alendronate and odanacatib treatments on bone mass, mechanical properties and bone remodeling in the lumbar spine of ovariectomized rabbits. J Bone Miner Res, 27(suppl 1)

75.

Sims NA, Martin TJ (2014) Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep 3(1):481PubMedPubMedCentral

76.

Soe K, Merrild DM, Delaisse JM (2013) Steering the osteoclast through the demineralization-collagenolysis balance. Bone 56(1):191–198CrossRefPubMed

77.

Stoch SA, Witter R, Hreniuk D, Liu C, Zajic S, Mehta A, Brandquist C, Dempsey C, Degroot B, Stypinski D, Denker A, Wagner JA (2013) Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration. Int J Clin Pharmacol Ther 51(3):688–692CrossRefPubMed

78.

Stoch SA, Witter R, Hrenuik D, Liu C, Zajic S, Mehta A, Chandler P, Morris D, Xue H, Denker A, Wagner JA (2013) Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin. J Popul Ther Clin Pharmacol 20(2):e312–e320PubMed

79.

Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, Scott BB, Panebianco D, Ding Y, Gottesdiener K, Wagner JA (2013) Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics–results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 75(1):1240–1254CrossRefPubMedPubMedCentral

80.

Stroup GB, Kumar S, Jerome CP (2009) Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 85:344–355CrossRefPubMed

81.

Williams DS, McCracken PJ, Purcell M, Pickarski M, Mathers PD, Savitz AT, Szumiloski J, Jayakar RY, Somayajula S, Krause S, Brown K, Winkelmann CT, Scott BB, Cook L, Motzel SL, Hargreaves R, Evelhoch JL, Cabal A, Dardzinski BJ, Hangartner TN, Duong LT (2013) Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 56(3):489–496CrossRefPubMed

82.

Xie H, Cui Z, Wang L, Xia Z, Hu Y, Xian L, Li C, Xie L, Crane J, Wan M, Zhen G, Bian Q, Yu B, Chang W, Qiu T, Pickarski M, Duong LT, Windle JJ, Luo X, Liao E, Cao X (2014) PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med 20(3):1270–1278CrossRefPubMedPubMedCentral

83.

Xue Y, Cai T, Shi S, Wang W, Zhang Y, Mao T, Duan X (2011) Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011. Orphanet J Rare Dis 6(2):20CrossRefPubMedPubMedCentral

84.

Yasuda Y, Kaleta J, Bromme D (2005) The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973–993CrossRefPubMed

Medicine Matters Rheumatology

Abstract